As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans to pull away from late-stage clinical trial investments in the area. More: Anti-vaccine sentiment pushes Moderna away from new late-stage infectious disease trials Source: fierce
read moreGLP-1 giant Eli Lilly has once again taken to the medium of short film to get an important message about obesity across. More: Lilly battles weight stigma in short film centering obesity conversation on health, not appearance Source: fierce
read moreThe new chairman of the CDC’s Advisory Committee on Immunization Practices, Kirk Milhoan, M.D., Ph.D., recently took to the podcast “Why Should I Trust You?” to answer exactly that. More: RFK Jr.'s new ACIP chair stresses 'individual autonomy,' questions polio
read moreST Pharm has struck a $56 million deal with an undisclosed U.S.-based biotech to produce active pharmaceutical ingredients (APIs) for a new oligonucleotide treatment. The Korean CDMO revealed the contract Friday in a regulatory filing. More: ST Pharm inks M
read moreA potential inflection point that Bausch Health hoped could diversify its portfolio has vanished with a pair of phase 3 failures for a new formulation of the company’s bread-and-butter Xifaxan—a setback that leaves a $2 billion hole in its growth
read moreWhile the threat of U.S. import tariffs prompted a surge in drug production last year, that output is slated to slow across multiple geographies in 2026, according to a new report from financial services firm Atradius. More: Global pharma manufacturing
read more© 1994 - 2026 B.M. Pharmaceuticals